Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine

Significantly Greater Proportion of Patients on Erenumab Experienced a 50 Percent or More Reduction in Number of Migraine Days Compared to Placebo Chronic Migraine Patients Experience 15 or More Headache Days per Month Erenumab is Co-Developed by Amgen and Novartis for the Prevention of Migraine

Amgen - Investors - RSS Content